Product Catalogue

View a listing of all Teva products.

Filters

Alphabet

Toggle

Product TA

Toggle

Molecule

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/​Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

respiratory-icon.png
Product TA:
Asthma
View product The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). The secondary objectives are: To evaluate the efficacy of Fp/ABS low dose compared to ABS and the effect on systemic corticosteroid (SCS) exposure. To evaluate the safety and tolerability of Fp/ABS.The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 42 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria.

Albuterol HFA MDI in Pediatric Participants With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Beclomethasone Dipropionate in Participants At Least 12 Years Old With Persistent Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Chronic-Dose Safety and Efficacy Study of Albuterol Inhaler in Pediatric Asthmatics

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Comparison of Albuterol Breath-Actuated Inhaler Versus Metered-Dose Inhaler in Participants With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Effectiveness and Safety of Fluticasone Propionate in Adolescents and Adults Who Have Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Effectiveness and Safety of Fluticasone Propionate in Adolescents and Adults Who Have Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Effectiveness of Albuterol Inhaler With Integrated Electronic Module Digital System

respiratory-icon.png
Product TA:
Asthma
View product This is a 12-week treatment, multicenter, open-label, randomized, parFemale, Maleel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, DHP (Cloud solution), and dashboard, to optimize outcomes in patients at least 13 years of age or older with asthma. The study will consist of a screening visit, a 12-week open-label treatment period, and a follow-up telephone cFemale, Male (2 weeks following treatment completion). Patients with suboptimal asthma control will be enrolled in the study and randomized in a 1:1 ratio to 1 of 2 parFemale, Maleel groups stratified by investigational center: DS group patients utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard, and CC group patients who will be treated with their standard of care albuterol-administering rescue inhalers and will not use the DS during the treatment period.

Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 and Older With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Efficacy and Safety of Fluticasone Propionate/​Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Primary objectives: The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module (Fp/ABS eMDPI). Secondary objective:To evaluate the efficacy of Fp/ABS eMDPI administered four times dailyTo evaluate the safety and tolerability of Fp/ABS eMDPI administered four times daily over four weeksTo investigate the pharmacokinetics of Fp/ABS eMDPI, ABS eMDPI and Fp eMDPI after administration of a single doseThe planned study duration for each participant is approximately 10 weeks, excluding an optional prescreening visit.

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Participants With Persistent Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Efficacy of QVAR vs. Flovent Diskus in Participants with Poorly Controlled Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Evaluation of Budesonide/Formoterol SPIROMAX® Versus SYMBICORT® TURBOHALER®

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Evaluation of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Fluticasone Propionate and Fluticasone Propionate/Salmeterol Compared to FLOVENT® DISKUS® and ADVAIR® DISKUS®

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Patients with Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Fluticasone Propionate Multidose Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Inhaler

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Fluticasone/Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® Compared to SYMBICORT® TURBOHALER®

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Non-invasive Measures of Distal Lung Disease in Asthmatics

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

PK and PD of Albuterol Spiromax® and ProAir® Hydrofluoroalkane in Pediatric Patients With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

QVAR Versus Placebo in Participants on a Stable Regimen of Inhaled Corticosteroids

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Safety and Efficacy of Beclomethasone Dipropionate in Participants 4-11 Years Old With Persistent Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Safety Study of Albuterol Spiromax® in Subjects With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

respiratory-icon.png
Product TA:
Asthma
View product The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) compared to the Standard of Care (SoC) group. The secondary objective is to describe the asthma management actions by investigational center health care providers (iHCPs) for Female, Male participants in both groups, to evaluate short-acting beta2 agonist (SABA) usage and the number of SABA-free days in the DS group, to evaluate adherence patterns to maintenance treatment (FS eMDPI) in the DS group, to assess behavioral correlates of responsiveness to digital health technology among patients for Female, Male participants in both groups, to evaluate work productivity and activity impairment in asthma patients in both groups, to assess the usability and acceptability of the DS by patients in the DS group and the investigational center personnel, and to evaluate the safety of FS eMDPI and Albuterol eMDPI.

Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Study to Evaluate Use of Albuterol Multidose Dry Powder Inhaler With an eModule in Participants With Asthma

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial

Study to measure the effectiveness of the Budesonide/formoterol electronic multidose dry powder inhaler (BF Digihaler) Digital System (DS)

respiratory-icon.png
Product TA:
Asthma
View product The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) compared to the Standard of Care group

Study to Test if TEV-48574 is Effective in Relieving Asthma

respiratory-icon.png
Product TA:
Asthma
View product The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA). The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control. The duration of patient participation in the study is planned to be up to approximately 30 weeks.

Study to Test if TEV-53275 is Effective in Relieving Asthma

respiratory-icon.png
Product TA:
Asthma
View product The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo. A secondary objective is to evaluate the efficacy of TEV-53275 compared to placebo assessed by lung function, asthma symptoms, rescue medication use, and quality of life measures. Another secondary objective is to evaluate the safety and tolerability of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype compared with placebo, and lastly, to evaluate the immunogenicity of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype. The planned study duration is approximately 16 months. The total duration of study participation is approximately 34 weeks including up to a 2-week screening period, a 2-week run-in period, a 16-week treatment period, and a follow-up visit 14 weeks after the final treatment visit.

Study Using PET/CT to Characterize the Effect of Reslizumab on Airway Inflammation

respiratory-icon.png
Product TA:
Asthma
View product Please refer to ClinicalTrials.gov for a description of the trial